Evidence map›Paper›PMID 31384956›Full record

Trial reportOsteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA2019

Serum fibroblast growth factor 23 and mineral metabolism in patients with euthyroid Graves' diseases: a case-control study.

C-H Lin, C-K Chang, C-W Shih, H-Y Li, K-Y Chen, W-S Yang, K-S Tsai, C-Y Wang, S-R Shih

2 registry-linked trialsAbstract readClinical Trial
PubMed Publisher
In one paragraph

Trial report in Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01660308 unknown statusnot on this map

Observing the Changes of Fibroblast Growth Factor 23 in Patients of Tumor Induced Osteomalacia

TypeobservationalSponsorNational Taiwan University HospitalRan2011 to 2016Enrolled40ConditionsHypophosphatemia
NCT02620085 unknown statusnot on this map

Bio-psycho-social Correlates of Psychological Distress in Patients With Graves' Disease in Euthyroid Status

TypeobservationalSponsorNational Taiwan University HospitalRan2011 to 2021Enrolled500ConditionsGraves' DiseaseArmsblood sampling
3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 4 citations in OpenAlex.

  1. Observational
  2. Non-Classical Effects of FGF23: Molecular and Clinical Features.International journal of molecular sciences · 2024
    Review
  3. New concepts in regulation and function of the FGF23.Clinical and experimental medicine · 2023
    Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

C-H LinDivision of Endocrinology and Metabolism, Department of Internal Medicine, National Taiwan University Hospital, Hsin-Chu Branch, Hsin-Chu, Taiwan.
C-K ChangDivision of Endocrinology and Metabolism, Department of Internal Medicine, Taipei City Hospital, Ren-Ai Branch, Taipei, Taiwan.
C-W ShihDepartment of Ophthalmology, Taipei City Hospital, Zhongxing Branch, Taipei, Taiwan.ORCID http://orcid.org/0000-0001-7424-1358
H-Y LiDivision of Endocrinology and Metabolism, Department of Internal Medicine, National Taiwan University Hospital, No. 1, Section 1, Ren-Ai Road, Taipei, 10051, Taiwan.
K-Y ChenAnsn Clinic, Hsin-Chu, Taiwan.
W-S YangDivision of Endocrinology and Metabolism, Department of Internal Medicine, National Taiwan University Hospital, No. 1, Section 1, Ren-Ai Road, Taipei, 10051, Taiwan.
K-S TsaiDivision of Endocrinology and Metabolism, Department of Internal Medicine, National Taiwan University Hospital, No. 1, Section 1, Ren-Ai Road, Taipei, 10051, Taiwan.
C-Y WangDivision of Endocrinology and Metabolism, Department of Internal Medicine, National Taiwan University Hospital, No. 1, Section 1, Ren-Ai Road, Taipei, 10051, Taiwan.
S-R ShihDivision of Endocrinology and Metabolism, Department of Internal Medicine, National Taiwan University Hospital, No. 1, Section 1, Ren-Ai Road, Taipei, 10051, Taiwan. srshih@ntu.edu.tw.
National Taiwan University · TWNational Taiwan University Hospital · TWTaipei City Hospital · TW

Funding

Liver Disease Prevention and Treatment Research Foundation, Taiwan, National Taiwan University Hospital 107-S3859
6 · The paper itself

Abstract

This study investigated the alterations of mineral metabolism in patients with Graves' disease (GD) who achieved euthyroidism. They had higher fibroblast growth factor 23 (FGF23) and phosphorus as compared with healthy subjects. Serum FGF23 was negatively correlated with serum phosphorus. These indicated abnormal mineral metabolism even after 1.6 years of euthyroid status.

introductionFGF23 is involved in the mineral homeostasis, especially the regulation of serum phosphorus. Graves' disease (GD) is associated with accelerated bone turnover, hyperphosphatemia, and elevated serum FGF23. Evidence suggested that serum FGF23 decreased after a 3-month treatment of GD. However, it remains unclear whether serum FGF23, serum phosphorus, and other markers of mineral metabolism will be normalized after euthyroid status achieved.

methodsA total of 62 patients with euthyroid GD and 62 healthy control subjects were enrolled, and the median duration of euthyroid status was 1.6 years. Endocrine profiles including thyroid function test, autoantibodies, serum FGF23, and bone turnover markers were obtained and compared between the two groups.

resultsEuthyroid GD patients had significantly higher serum FGF23 and phosphorus, and lower 25-hydroxyvitamin D (25(OH)D) and intact parathyroid hormone (iPTH) levels as compared with the control group. Serum FGF23 was significantly and negatively correlated with phosphorus level after adjusted for age, gender, calcium, iPTH, and 25(OH)D in the euthyroid GD group.

conclusionSerum phosphorus and FGF23 levels remain higher in GD patients even after euthyroid status has been achieved for a median of 1.6 years. Serum FGF23 was negatively correlated with serum phosphorus in euthyroid GD patients. Underlying mechanisms warrant further investigations.

trial registrationRegistration number: NCT01660308 and NCT02620085.

Indexed as

AdultAgedAged, 80 and overBiomarkersBone and BonesBone RemodelingCalciumCase-Control StudiesFemaleFibroblast Growth Factor-23Fibroblast Growth FactorsGraves DiseaseHumansMaleMiddle AgedMinerals25-hydroxyvitamin DBiomarkersCalciumFGF23 protein, humanFibroblast Growth Factor-23Fibroblast Growth FactorsMineralsParathyroid HormonePhosphorusVitamin DFibroblast growth factor 23Graves’ diseaseOsteoporosisPhosphorus

Identifiers

PMID31384956
OpenAlexW2966847827

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.